Short telomeres: A novel potential predictor of relapse in Ewing sarcoma

Clinical Cancer Research

Volumn 13, Issue 19, 2007, Pages 5777-5783

  Avigad, Smadar ^a,b   Naumov, Inna ^a   Ohali, Anat ^a,b   Jeison, Marta ^b   Berco, Gili Halevy ^b   Mardoukh, Jacques ^b   Stark, Batia ^b   Ash, Shifra ^b   Cohen, Ian J ^b   Meller, Isaac ^a   Kollender, Yehuda ^a   Issakov, Josephine ^a   Yaniv, Isaac ^a,b  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; ANEUPLOIDY; ARTICLE; CANCER LOCALIZATION; CANCER RELAPSE; CANCER RISK; CHILD; CHROMOSOMAL INSTABILITY; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; EWING SARCOMA; FEMALE; HUMAN; LYMPHOCYTE; MALE; PRIORITY JOURNAL; PROGNOSIS; TELOMERE;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; CHROMOSOMAL INSTABILITY; CHROMOSOMES; FEMALE; HUMANS; INFANT; MALE; MULTIVARIATE ANALYSIS; NUCLEIC ACID HYBRIDIZATION; PROGNOSIS; RECURRENCE; RISK; RISK FACTORS; SARCOMA, EWING'S; TELOMERE; TREATMENT OUTCOME;

EID: 35348855217     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0308     Document Type: Article

References (48)

1. Ginsberg JP, Woo SY, Johnson ME, Hick MJ, Horowitz ME. Ewing sarcoma family of tumors: Ewing's sarcoma of bone and soft tissue and the peripheral primitive neuroectodermal tumors. 4th ed. In: Pizzo PA, Poplack DG, editors. Principles and Practice of Pediatric Oncology. Philadelphia: Lippincott-Raven; 2002. p. 973-1016.
2. Delattre O, Zucman J, Melot T, et al. The Ewing family of tumors: a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Eng J Med 1994;331:294-9.
3. Sorensen PH, Lessnick SL, Lopez-Terrada D, Liu XF, Triche TJ, Denny CT. A second Ewing's sarcoma translocation, t(21; 22), fuses the EWS gene to another ETS-family transcription factor, ERG. Nat Genet 1994;6:146-51.
4. Jeon I-S, Davis JN, Braun BS, et al. A variant Ewing's sarcoma translocation (7:22) fuses the EWS gene to the ETS gene ETV1. Oncogene 1995;10:1229-34.
5. Urano F, Umezawa A, Hong W, Kikuchi H, Hata J. A novel chimera gene between EWS and E1A-F, encoding the adenovirus E1A enhancer-binding protein, in extraosseous Ewing's sarcoma. Biochem Biophys Res Commun 1996;219:608-12.
6. Peter M, Couturier J, Paquement H, et al. A new member of the ETS family fused to EWS in Ewing tumors. Oncogene 1997;14:1159-64.
7. Terrier P, Llombart-Bosch A, Contesso G. Small round blue cell tumors in bone: prognostic factors correlated to Ewing's sarcoma and neuroectodermal tumors. Semin Diagn Pathol 1996;13:250-7.
8. Moyzis RK, Buckingham JM, Cram LS, et al. A highly conserved repetitive DNA sequence (TTAGGG)n present at the telomeres of human chromosomes. Proc Natl Acad Sci U S A 1988;85:6622-6.
9. Blackburn EH. Structure and function of telomere. Nature 1991;350:569-73.
10. Zakian VA. Telomeres: beginning to understand the end. Science 1995;270:1601-7.
11. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fibroblasts. Proc Natl Acad Sci U S A 1992;89:10114-8.
12. Nugent CI, Lundblad B. The telomerase reverse transcriptase: components and regulation. Genes Dev 1998;12:1073-85.
13. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer 1997;33:787-91.
14. Hastie ND, Dempster M, Dunlop MG, Thompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990;346:866-71.
15. Adamson DJA, King DJ, Haits NE. Significant telomere shortening in childhood leukemia. Cancer Genet Cytogenet 1992;61:204-6.
16. Hiyama E, Hiyama K, Yokoyama T, Ichikawa T, Matsuura Y. Length of telomeric repeats in neuroblastoma: correlation with prognosis and other biological characteristics. Jpn J Cancer Res 1992;83:159-64.
17. Hiraga S, Ohnishi T, Izumoto S, et al. Telomerase activity and alterations in telomere length in human brain tumors. Cancer Res 1998;58:2117-25.
18. Franco S, Ozkaynak MF, Sandoval C, et al. Telomere dynamics in childhood leukemia and solid tumors: a follow up study. Leukemia 2003;17:401-10.
19. Ducray C, Pommier JP, Martins L, Boussin FD, Sabatier L. Telomere dynamics, end to end fusions and telomerase activation during the human fibroblast immortalization process. Oncogene 1999;18:4211-23.
20. Hackett JA, Greider CW. Balancing instability: dual roles for telomerase and telomere dysfunction in tumorigenesis. Oncogene 2002;21:619-26.
21. Bisoffi M, Heaphy CM, Griffith JK. Telomeres: prognostic markers for solid tumors. Int J Cancer 2006;119:2255-60.
22. Fordyce CA, Heaphy CM, Bisoffi M, et al. Telomere content correlates with stage and prognosis in breast cancer. Breast Cancer Res Treat 2006;99:193-202.
23. Donaldson L, Fordyce C, Gilliland F, et al. Association between outcome and telomere DNA content in prostate cancer. J Urol 1999;162:1788-92.
24. Garcia-Aranda C, de Juan C, Diaz-Lopez A, et al. Correlations of telomere length, telomerase activity and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer 2006;106:541-51.
25. Wu K-D, Orme LM, Shaughnessy J, Jacobson J, Barlogie B, Moore MAS. Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status and overall survival. Blood 2003;101:4982-9.
26. Grabowski P, Hultdin M, Karlsson K, et al. Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. Blood 2005;105:4807-12.
27. Ohali A, Avigad S, Ash S, et al. Telomere length is a prognostic factor in neuroblastoma. Cancer 2006;107:1391-9.
28. Harley CB, Futcher AB, Greider CW. Telomeres shorten during aging of human fibroblasts. Nature 1990;345:458-60.
29. Amiel A, Ohali A, Fejgin M, et al. Molecular cytogenetic parameters in Ewing sarcoma. Cancer Genet Cytogenet 2003;140:107-12.
30. Mitelman F. An International System for Human Cytogenetic Nomenclature. Basel: Karger; 1995.
31. Montgomery E, Argani P, Hicks JL, DeMarzo AM, Meeker AK. Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically. Am J Pathol 2004;164:1523-9.
32. Ulaner GA, Hoffman AR, Otero J, et al. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosomes Cancer 2004;41:155-62.
33. Griffith JK, Bryant JE, Fordyce CA, Gilliland FD, Joste NE, Moyzis RK. Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma. Breast Cancer Res Treat 1999;54:59-64.
34. Fordyce CA, Heaphy CM, Joste NE, Smith AY, Hunt WC, Griffith JK. Association between cancer-free survival and telomere DNA content in prostate tumors. J Urol 2005;173:610-4.
35. Patel MM, Parekh LJ, Jha FP, et al. Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Head Neck 2002;24:1060-7.
36. Ohali A, Avigad S, Cohen IJ, et al. Association between telomerase activity and outcome in patients with nonmetastatic Ewing family of tumors. J Clin Oncol 2003;21:3836-43.
37. Yan P, Benhatter J, Coindre J-M, Guillou L. Telomerase activity and hTERT mRNA expression can be heterogeneous and does not correlated with telomere length in soft tissue sarcomas. Int J Cancer 2002;98:851-6.
38. Didiano D, Shalaby T, Lang D, Grotzer M. A telomere maintenance in childhood primitive neuroectodermal brain tumors. Neuro-Oncol 2004;6:1-8.
39. Takagi S, Kinouchi Y, Hiwatashi N, etal. Telomere shortening and the clinicopathologic characteristics of human colorectal carcinomas. Cancer 1999;86:1431-6.
40. Hattinger CM, Potschger U, Tarkkanen M, et al. Prognostic impact of chromosomal aberrations in Ewing tumours. Br J Cancer 2002;86:1763-9.
41. Kullendorff C-M, Mertens F, Donner M, Wiebe T, Akerman M, Mandahl N. Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome? Med Pediatr Oncol 1999;32:79-83.
42. Tarkkanen M, Kiuru-Kuhlefelt S, Blomqvist C, et al. Clinical correlations of genetic changes by comparative genomic hybridization in Ewing sarcoma and related tumors. Cancer Genet Cytogenet 1999;114:34-41.
43. Ohali A, Avigad S, Cohen IJ, High frequency of genomic instability in Ewing family of tumors. Cancer Genet Cytogenet 2004;150:50-6.
44. Finley JC, Reid BJ, Odze RD, et al. Chromosomal instability in Barett's esophagus is related to telomere shortening. Cancer Epidemiol Biomarkers Prev 2006;15:1451-7.
45. Hartmann U, Brummendorf TH, Balabanov S, Thiede C, Illme T, Schaich M. Telomere length and hTERT expression in patients with acute myeloid leukemia correlates with chromosomal abnormalities. Haematologica 2005;90:307-16.
46. Swiggers SJ, Kuijpers MA, de Cort MJM, Beverloo HB, Zijlmans JMJM. Critically short telomeres in acute myeloid leukemia with loss or gain of parts of chromosomes. Genes Chromosomes Cancer 2006;45:247-56.
47. Heaphy CM, Bisoffi M, Fordyce CA, et al. Telomere DNA content and allelic imbalance demonstrate field cancerization in histologically normal tissue adjacent to breast tumors. Int JCancer 2006;119:108-16.
48. Ohali A, Avigad S, Zaizov R, et al. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 2004;23:8997-9006.